SPY334.33+2.22 0.67%
DIA273.90+1.90 0.70%
IXIC11,108.07+109.67 1.00%

Credit Suisse Downgrades AcelRx Pharmaceuticals to Neutral, Lowers Price Target to $2

Credit Suisse downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Outperform to Neutral and lowers the price target from $7 to $2.

Benzinga · -

Credit Suisse downgrades AcelRx Pharmaceuticals (NASDAQ:ACRX) from Outperform to Neutral and lowers the price target from $7 to $2.